Rubicon Research Limited

General Atlantic Singapore RR Pte Ltd, a promoter, sold 1,38,53,073 shares of Rubicon Research Limited for ₹2299.61 crore at ₹1660.00 apiece on August 26, 2026, reducing its stake from 35.70% to 27.34%. This transaction was part of a larger sale over two days, bringing the total reduction in promoter holding to 8.45%.

A pharmaceutical company engaged in the development, manufacturing, and commercialization of differentiated drug formulations across multiple therapeutic areas. Incorporated in 1999, the company specializes in creating specialized formulations that address specific medical needs in the Indian healthcare market. Its integrated operations span research and development, manufacturing of quality pharmaceuticals, and distribution. The company distinguishes itself through its focus on bringing innovative, differentiated solutions to patients and healthcare providers.